Structure-activity relationships of fluorene compounds inhibiting HCV variants

Title
Structure-activity relationships of fluorene compounds inhibiting HCV variants
Authors
배애님금교창가디 장데부 고라크스나트김희선유영수문재곤문희조코하라김병문장승기Jae Seung Lee
Keywords
Hepatitis c virus; Direct-acting antiviral agent (DAA); NS5A inhibitor; Resistance-associated variant (RAV); Structure-activity relationship (SAR); Molecular docking
Issue Date
2020-02
Publisher
Antiviral research
Citation
VOL 174, 104678
Abstract
Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths annually. Effective direct-acting antiviral agents (DAAs) have been developed and are currently used for HCV treatment targeting the following three proteins: NS3/4A proteinase that cleaves the HCV polyprotein into various functional proteins, RNA-dependent RNA polymerase (designated as NS5B), and NS5A, which is required for the formation of double membrane vesicles serving as RNA replication organelles. At least one compound inhibiting NS5A is included in current HCV treatment regimens due to the high efficacy and low toxicity of drugs targeting NS5A. Here we report fluorene compounds showing strong inhibitory effects on GT 1b and 3a of HCV. Moreover, some compounds were effective against resistance-associated variants to DAAs. The struc
URI
http://pubs.kist.re.kr/handle/201004/71976
ISSN
0166-3542
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE